Incidence and prevalence of inflammatory myopathies: A systematic review

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 50-63

  Meyer, Alain ^a,b,c   Meyer, Nicolas ^b   Schaeffer, Mickael ^b   Gottenberg, Jacques Eric ^a   Geny, Bernard ^b,c   Sibilia, Jean ^a  

^a Centre de Référence des Maladies Auto immunes Rares   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Dermatomyositis; Epidemiology; Incidence; Inclusion body myositis; Inflammatory myopathies; Meta analysis; Polymyositis; Prevalence

Indexed keywords

HLA DR3 ANTIGEN;

ARTHRITIS; ARTICLE; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; ENVIRONMENTAL FACTOR; HUMAN; ICD-9; INCIDENCE; INCLUSION BODY MYOSITIS; IRELAND; JUVENILE MYOSITIS; META ANALYSIS (TOPIC); MOTOR NEURON DISEASE; MULTICENTER STUDY (TOPIC); MYOSITIS; NEW ZEALAND; PREVALENCE; PRIORITY JOURNAL; SENESCENCE; SPATIOTEMPORAL ANALYSIS; SPORADIC INCLUSION BODY MYOSITIS; SWEDEN; SYSTEMATIC REVIEW; TIME; ULTRAVIOLET RADIATION; UNITED KINGDOM; UNITED STATES;

EID: 84928732294     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu289     Document Type: Article

References (73)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
3. Hilton-Jones D. Observations on the classification of the inflammatory myopathies. Presse Med Paris Fr 2011;40: e199-208.
4. Pearson M. Polymyositis. Annu Rev Med 1966;17:63-82.
5. Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain J Neurol 1966;89:747-68.
6. Kurland LT, Hauser WA, Ferguson RH et al. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus. Mayo Clin Proc 1969;44:649-63.
7. Medsger TA Jr, Dawson WN Jr, Masi AT. The epidemiology of polymyositis. Am J Med 1970;48:715-23.
8. Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960-76. Isr J Med Sci 1980;16:197-200.
9. Radhakrishnan K, el-Mangoush MA, Gerryo SE. Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol Scand 1987;75: 95-100.
10. Araki S, Uchino M, Kumamoto T. Prevalence studies of multiple sclerosis, myasthenia gravis, and myopathies in Kumamoto district, Japan. Neuroepidemiology 1987;6: 120-9.
11. Oddis CV, Conte CG, Steen VD et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990;17:1329-34.
12. Ahlström G, Gunnarsson LG, Leissner P et al. Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county. Neuroepidemiology 1993;12:262-9.
13. Kusumi M, Nakashima K, Nakayama H et al. Epidemiology of inflammatory neurological and inflammatory neuromuscular diseases in Tottori Prefecture, Japan. Psychiatry Clin Neurosci 1995;49:169-74.
14. Weitoft T. Occurrence of polymyositis in the county of Gävleborg, Sweden. Scand J Rheumatol 1997;26:104-6.
15. Patrick M, Buchbinder R, Jolley D et al. Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J Rheumatol 1999;26: 1094-100.
16. El-Tallawy HN, Khedr EM, Qayed MH et al. Epidemiological study of muscular disorders in Assiut, Egypt. Neuroepidemiology 2005;25:205-11.
17. Bernatsky S, Joseph L, Pineau CA et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009;68:1192-6.
18. Kuo C-F, See L-C, Yu K-H et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 2011;165: 1273-9.
19. Tran T, Steffey A, Caspard H. Epidemiology of idiopathic inflammatory myopathies in England-a database analysis. Ann Rheum Dis 2012;71:465.
20. Barnabe C, Joseph L, Bélisle P et al. Prevalence of autoimmune inflammatory myopathy in the first nations population of Alberta, Canada. Arthritis Care Res 2012;64: 1715-9.
21. Yu K-H, See L-C, Kuo C-F et al. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res 2013;65:244-50.
22. Vincze M, Griger M, Dankó K. Epidemiological data of patients with idiopathic inflammatory myopathy from a Hungarian myositis centre. Ann Rheum Dis 2013; 72:650.
23. Gupta R, Gow PJ. Inflammatory myopathies-a review of newly diagnosed patients (2004-2008) in the Counties Manukau region. N Z Med J 2013;126:89-95.
24. Ohta A, Nagai M, Nishina M et al. Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod Rheumatol 2014;24:477-80.
25. Koh ET, Seow A, Ong B et al. Adult onset polymyositis/ dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993; 52:857-61.
26. Kaipiainen-Seppä nen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med 1996;240:81-4.
27. Lynn SJ, Sawyers SM, Moller PW et al. Adult-onset inflammatory myopathy: North Canterbury experience 1989-2001. Intern Med J 2005;35:170-3.
28. Limaye V, Blumbergs P, Scott G et al. The epidemiology of dermatomyositis in South Australia. APLAR J Rheumatol 2007;10:94-100.
29. Anagnostopoulos I, Zinzaras E, Alexiou I et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord 2010;11:98.
30. Furst DE, Amato AA, Iorga ŞR et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012;45:676-83.
31. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 2012; 13:103.
32. Tan JA, Roberts-Thomson PJ, Blumbergs P et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 2013;16: 331-8.
33. Rosa J, Garrot LF, Navarta DA et al. Incidence and prevalence of polymyositis and dermatomyositis in a health management organization in Buenos Aires. J Clin Rheumatol 2013;19:303-7.
34. Denardo BA, Tucker LB, Miller LC et al. Demography of a regional pediatric rheumatology patient population. Affiliated Children's Arthritis Centers of New England. J Rheumatol 1994;21:1553-61.
35. Pelkonen PM, Jalanko HJ, Lantto RK et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 1994; 21:2143-6.
36. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995;34:732-6.
37. Mendez EP, Lipton R, Ramsey-Goldman R et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49: 300-5.
38. Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr Jpn 1997;39:242-4.
39. Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord 2000;10:1-9.
40. Lindberg C, Persson LI, Bjö rkander J et al. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994; 89:123-31.
41. Badrising UA, Maat-Schieman M, van Duinen SG et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55: 1385-7.
42. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-2.
43. Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine 2001;80:320-7.
44. Wilson FC, Ytterberg SR, St Sauver JL et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008;35: 445-7.
45. Needham M, Corbett A, Day T et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008;15: 1350-3.
46. Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/ Turkey: a muscle biopsy based survey. Acta Myol 2011; 30:34-6.
47. Findlay GH, Whiting DA, Simson IW. Dermatomyositis in the Transvaal and its occurrence in the Bantu. South Afr Med J 1969;43:694-7.
48. Couchman KG, Wigley RD. The distribution of the systemic connective tissue diseases, ulcerative colitis and Crohn's disease in New Zealand: an analysis of hospital admission statistics. N Z Med J 1971;74:231-3.
49. Bendewald MJ, Wetter DA, Li X et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010;146:26-30.
50. Tanimoto K, Nakano K, Kano S et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22:668-74.
51. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 2002;28:723-41.
52. Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
53. Verschuuren JJ, Badrising UA, Wintzen AR et al. Inclusion body myositis. In: Emery AEH, ed. Diagnostic Criteria for Neuromuscular Disorders. London: Royal Society of Medicine Press, 1997:81-4.
54. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6: 620-31.
55. Hengstman GJ, van Venrooij WJ, Vencovsky J et al. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000;59:141-2.
56. Okada S, Weatherhead E, Targoff IN et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48:2285-93.
57. Love LA, Weinberg CR, McConnaughey DR et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 2009;60:2499-504.
58. Middleton D, Menchaca L, Rood H et al. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003;61:403-7.
59. Mastaglia FL. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol 2009;28:66-71.
60. Lampe JB, Gossrau G, Kempe A et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol 2003;250:1313-7.
61. Leff RL, Burgess SH, Miller FW et al. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum 1991;34: 1391-6.
62. Phillips BA, Zilko PJ, Garlepp MJ et al. Seasonal occurrence of relapses in inflammatory myopathies: a preliminary study. J Neurol 2002;249:441-4.
63. Sarkar K, Weinberg CR, Oddis CV et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum 2005;52: 2433-8.
64. Pachman LM, Lipton R, Ramsey-Goldman R et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005;53:166-72.
65. Manlhiot C, Liang L, Tran D et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology 2008;47:526-9.
66. Sibilia J, Chatelus E, Meyer A et al. [How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies]. Presse Med 2010;39: 1010-25.
67. van der Meulen MFG, Bronner IM, Hoogendijk JE et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316-21.
68. Troyanov Y, Targoff IN, Tremblay J-L et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005;84: 231-49.
69. Hoogendijk JE, Amato AA, Lecky BR et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14: 337-45.
70. De Bleecker JL, Lundberg IE, de Visser M et al. 193rd ENMC International workshop: pathology diagnosis of idiopathic inflammatory myopathies, 30 November-2 December 2012, Naarden, The Netherlands. Neuromuscul Disord 2013;23:945-51.
71. Wittes JT, Colton T, Sidel VW. Capture-recapture methods for assessing the completeness of case ascertainment when using multiple information sources. J Chronic Dis 1974;27:25-36.
72. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain 1975;98:637-66.
73. Gerami P, Schope JM, McDonald L et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sinémyositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006;54:597-613.